Dr James Clark, B.Sc Ph.D
James has held senior and executive roles in pharmaceutical and personalised medicine companies, GlaxoSmithKline-Biologicals and the personalised medicine company Response Genetics respectively. He has a PhD from Glasgow University, a BSc (Hons, 1st class) in Microbiology from Heriot-Watt University, and has published extensively in molecular oncology and cardiovascular genetics. Within GSK-Biologicals James was a Molecular Biology technology group head for the cancer vaccine program. His responsibilities were to develop biomarkers and assays to be implemented in the Mage-3 cancer vaccine clinical trials. During the time at GSK-Biologicals he was involved in developing the mage-3 gene expression theranostic which is currently in the final stages of clinical development. Also, he developed a predictive gene profile for response to the mage-3 cancer vaccine which was the first patented profile of its type in GSK. Within Response Genetics James was responsible for global operations and the strategic development and management of the UK based molecular genetics laboratory. Within this role James managed biomarker validation and commercialisation of personalised medicine products for Europe. During this time he successfully developed CE marking for the ResponseDx personalised medicine test and developed a reimbursement strategy for both UK and European health care markets.
James established Permedx in August 2009 to satisfy a growing need for the development and commercialisation of translational and personalised medicine. Permedx has recently expanded its services and capabilities through a number of strategic partnerships with regulatory and reimbursement experts. This ensures we can offer a full range of services from early biomarker discovery through to commercialisation, reimbursement and regulatory.